This study is in progress, not accepting new patients
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Summary
- Eligibility
- for people ages 18-90 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Links
- CARDIO-TTRansform Website
- ID
- NCT04136171
- Phase
- Phase 3 Cardiomyopathy Research Study
- Study Type
- Interventional
- Participants
- About 1438 people participating
- Last Updated